2,4,5-Trifluorophenylaceticum Acidum CAS 209995-38-0 Puritas ≥99.5% (GC) Sitagliptin Phosphate Monohydrate Intermedia Featured Image

2,4,5-Trifluorophenylaceticum Acidum CAS 209995-38-0 Puritas ≥99.5% (GC) Sitagliptin Phosphate Monohydratum medium

Description:

Nomen chemicum: 2,4,5-Trifluorophenylaceticum Acid

CAS: 209995-38-0

Puritas: ≥99.5% (GC)

Aspectus: Alba ad Off-White pulveris

Sitagliptin phosphatis monohydratorum intermedium (CAS: 654671-77-9) ad tractationem generis diabete 2

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Supple Sitagliptin Phosphate Monohydratorum intermedia:
Sitagliptin API CAS 486460-32-6
Sitagliptin Phosphate Monohydratum API CAS 654671-77-9
Acidum trifluorophenylaceticum 2,4,5-
Boc-(R)-3-Amino-4-(2,4,5-Trifluoro-Phenyl)-Butyric Acidum CAS 486460-00-8
Sitagliptin Triazole Hydrochloride CAS 762240-92-6
Sitagliptin Phosphate Monohydratum Intermediate CAS 486460-21-3

Chemical Properties:

Nomen chemicum	2,4,5-Trifluorophenylacetic Acid
CAS Number	200995-38-0
CATTUS Number	RF-PI1191
Stock Status	In Stock, Productio Ascendite ad Tons
Formulae hypotheticae	C8H5F3O2
M. Pondus	190.12
Liquescens punctum	121.0 ad 125.0℃
Solubilitas	Solutum in Methanol
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Alba ad Off-White pulveris
Puritas / Analysis Methodus	≥99.5% (GC)
Humor (KF)	≤0.50%
Residere in Igniton	≤0.50%
Totalis immunditias	≤0.50%
Test Standard	Enterprise Standard
Consuetudinem	Sitagliptin Phosphate Monohydratorum medium (CAS: 654671-77-9)

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris.

Repono Condition:Repone in vasis signatis in loco frigido et sicco;A luce et humore protege.

commoda:

FAQ:

Applicatio:

Acidulum trifluorophenylaceticum (CAS: 209995-38-0) medium est phosphatis Sitagliptini Monohydratis (CAS: 654671-77-9).Sitagliptin phosphatum (STG) tractare DM specie 2 adhibetur, quia imperium glycemicum auget augendo gradus incretinorum hormonum activorum, GLP-I (peptide-1) et GIP (glucoso-dependens insulinotropico peptidis).Activatio harum incretinarum in cellulis β-pancreaticis auctas facit gradus monophosphatis cyclici adenosini et calcii intracellulares, cum secretione insulina subsequente glucose-dependens (2).Hoc medicamentum hypoglycemicum ad novum genus pertinet, quod dipeptidylum peptidase IV inhibitores vocatur.STG a FDA in 2006 probatus est.